Journal
MARINE DRUGS
Volume 16, Issue 2, Pages -Publisher
MDPI
DOI: 10.3390/md16020053
Keywords
crambescidin 800; triple-negative breast cancer; marine sponge
Categories
Funding
- Australian Research Council [FT130101767]
- Cancer Council of Western Australia Research Fellowship
- National Health and Medical Research Council [APP1069308]
- National Institutes of Health [R01CA170370]
- National Breast Cancer Foundation [NC-14-024, PF-15-001]
- National Breast Cancer Foundation [PF-15-001] Funding Source: researchfish
- Australian Research Council [FT130101767] Funding Source: Australian Research Council
Ask authors/readers for more resources
Triple negative breast cancer (TNBC) is currently the only group of breast cancers without an effective targeted therapy. Marine sponges have historically been a source of compounds with anticancer activity. In this study, we screened extracts from twenty marine sponges collected off the coast of Western Australia for cytotoxic activity against TNBC cells. One very active extract derived from the sponge Monanchora viridis was selected for bioactivity-guided fractionation. Through multiple steps of purification, we isolated a potent cytotoxic compound, which was identified as crambescidin 800 (C800). We found that C800 exhibited cytotoxic potency in a panel of breast cancer cells, of which TNBC and luminal cancer cell models were the most sensitive. In addition, C800 induced cell cycle arrest at the G2/M phase, resulting in a decline in the expression of cyclin D1, CDK4, and CDK6 in TNBC cells. This effect was associated with the inhibition of phosphorylation of Akt, NF-B, and MAPK pathways, resulting in apoptosis in TNBC cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available